Regen BioPharma Inc (OTCMKTS: RGBP) share has started going up the charts as it broke it’s high and looked to break out of its trading range and make a run on its recent highs of $0.081 in April.
Stock market high achieved after company subsidiary enters agreement with Oncology Pharma Inc (OTCMKTS: ONPH)
The high was achieved after Regen, and its subsidiary KLS arrived into an agreement with Oncology Pharma Inc (OTCMKTS: ONPH). Under the terms of the agreement, Regen granted Oncology Pharma the rights to market curtains copyrights that dealt with humans suffering from pancreatic cancer. The period of the covenant is 15 years.
The License IP contains antigen precise cancer serums in which altered mRNA is directed to produce epitopes able to yield an exempt response that expands the probability of fruitful induction of immunity. An epitope is the portion of an antigen that is accepted by the resistant system.
The company is in the news again after it declared that it had been notified by the United States Patent and Trademark Office that copyright defense shall be allowed to it with respect to “METHODS AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION.”
RGBP takeover buzzes thrive
As per many investors, there is a real chance that the company may be bought over by a major pharmaceutical company like Precigen or others. The purchase of RGBP would make sense as the CEO of Precigen, Helen Sabzevari, is a member of the former Scientific Advisory Board.
PGEN is listed on NASDAQ and has a market capitalization of $1.3 billion. The company has a large scientific trials pipeline in the areas of Immunology and Oncology, which includes the development of mRNA vaccines.
Regenis shares similar scientific market of Oncology-Immunology applicant drug development that Precigen is presently in. This would make Regenis an ideal acquisition candidate for Precigen. In addition, the CEO of Regenis, David Koos, is pushing things aggressively in his company to make it an attractive candidate for a buyout.